Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 113438166 | 11343816 | 6 | F | 201407 | 20160811 | 20150806 | 20160817 | EXP | PHHY2014CA092176 | NOVARTIS | 80.60 | YR | F | Y | 0.00000 | 20160817 | CN | COUNTRY NOT SPECIFIED | CA |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 113438166 | 11343816 | 1 | SS | XOLAIR | OMALIZUMAB | 1 | Subcutaneous | 150 MG, EVERY 4 WEEKS | U | 0 | 150 | MG | VIAL | ||||||
| 113438166 | 11343816 | 2 | SS | XOLAIR | OMALIZUMAB | 1 | Subcutaneous | UNK | U | 0 | VIAL | ||||||||
| 113438166 | 11343816 | 3 | SS | XOLAIR | OMALIZUMAB | 1 | Subcutaneous | UNK | U | 0 | VIAL | ||||||||
| 113438166 | 11343816 | 4 | SS | XOLAIR | OMALIZUMAB | 1 | Subcutaneous | UNK | U | 0 | VIAL | ||||||||
| 113438166 | 11343816 | 5 | SS | XOLAIR | OMALIZUMAB | 1 | Subcutaneous | UNK | U | 0 | VIAL | ||||||||
| 113438166 | 11343816 | 6 | SS | XOLAIR | OMALIZUMAB | 1 | Subcutaneous | UNK | U | 0 | VIAL | ||||||||
| 113438166 | 11343816 | 7 | SS | XOLAIR | OMALIZUMAB | 1 | Subcutaneous | UNK | U | 0 | VIAL | ||||||||
| 113438166 | 11343816 | 8 | SS | XOLAIR | OMALIZUMAB | 1 | Subcutaneous | UNK | U | S0065E | 0 | VIAL | |||||||
| 113438166 | 11343816 | 9 | PS | DIOVAN | VALSARTAN | 1 | Unknown | UNK | U | 20665 | |||||||||
| 113438166 | 11343816 | 10 | SS | METOPROLOL. | METOPROLOL | 1 | Unknown | 50 MG | U | 0 | 50 | MG | |||||||
| 113438166 | 11343816 | 11 | C | APO CANDESARTAN | 2 | Unknown | 4 MG, | U | 0 | 4 | MG | ||||||||
| 113438166 | 11343816 | 12 | C | PMS AMLODIPINE | 2 | Unknown | 2.5 MG | U | 0 | 2.5 | MG | ||||||||
| 113438166 | 11343816 | 13 | C | VENTOLIN | ALBUTEROL SULFATE | 1 | Unknown | UNK, PRN | U | 0 | |||||||||
| 113438166 | 11343816 | 14 | C | FLOVENT | FLUTICASONE PROPIONATE | 1 | Unknown | UNK UNK, QID | U | 0 | QID | ||||||||
| 113438166 | 11343816 | 15 | C | ADVAIR HFA | FLUTICASONE PROPIONATESALMETEROL XINAFOATE | 1 | Unknown | UNK UNK, QID | U | 0 | QID | ||||||||
| 113438166 | 11343816 | 16 | C | CANDESARTAN | CANDESARTAN | 1 | Unknown | U | 0 | ||||||||||
| 113438166 | 11343816 | 17 | C | AMLODIPINE | AMLODIPINE BESYLATE | 1 | Unknown | UNK | U | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 113438166 | 11343816 | 1 | Asthma |
| 113438166 | 11343816 | 9 | Product used for unknown indication |
| 113438166 | 11343816 | 10 | Product used for unknown indication |
| 113438166 | 11343816 | 11 | Product used for unknown indication |
| 113438166 | 11343816 | 12 | Product used for unknown indication |
| 113438166 | 11343816 | 13 | Product used for unknown indication |
| 113438166 | 11343816 | 14 | Product used for unknown indication |
| 113438166 | 11343816 | 15 | Product used for unknown indication |
| 113438166 | 11343816 | 16 | Product used for unknown indication |
| 113438166 | 11343816 | 17 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 113438166 | 11343816 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 113438166 | 11343816 | Asthenia | |
| 113438166 | 11343816 | Asthma | |
| 113438166 | 11343816 | Blood pressure decreased | |
| 113438166 | 11343816 | Bronchitis | |
| 113438166 | 11343816 | Chest pain | |
| 113438166 | 11343816 | Cough | |
| 113438166 | 11343816 | Drug hypersensitivity | |
| 113438166 | 11343816 | Fatigue | |
| 113438166 | 11343816 | Feeling abnormal | |
| 113438166 | 11343816 | Hyperhidrosis | |
| 113438166 | 11343816 | Hypertension | |
| 113438166 | 11343816 | Influenza like illness | |
| 113438166 | 11343816 | Lethargy | |
| 113438166 | 11343816 | Malaise | |
| 113438166 | 11343816 | Nasal congestion | |
| 113438166 | 11343816 | Productive cough | |
| 113438166 | 11343816 | Rales | |
| 113438166 | 11343816 | Respiratory rate increased | |
| 113438166 | 11343816 | Seasonal allergy | |
| 113438166 | 11343816 | Sinus congestion | |
| 113438166 | 11343816 | Skin discolouration | |
| 113438166 | 11343816 | Tachycardia | |
| 113438166 | 11343816 | Wheezing |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 113438166 | 11343816 | 1 | 20140703 | 0 | ||
| 113438166 | 11343816 | 2 | 20140828 | 0 | ||
| 113438166 | 11343816 | 3 | 20141218 | 0 | ||
| 113438166 | 11343816 | 4 | 20150115 | 0 | ||
| 113438166 | 11343816 | 5 | 20150730 | 0 | ||
| 113438166 | 11343816 | 6 | 20151030 | 0 | ||
| 113438166 | 11343816 | 7 | 20160421 | 0 | ||
| 113438166 | 11343816 | 8 | 20160519 | 0 |